

Discovery Services

Certificate of Analysis

PrKX, active

(Recombinant enzyme expressed in Sf21 insect cells) Item # 14-677, 14-677-K, 14-677M Parent Lot # 32835U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run

Product Description: *N*-terminal 6Histagged, recombinant, full length, human PrKX expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 92% by SDS-PAGE and Coomassie blue staining. MW = 44.7kDa.

Specific Activity (Parent lot# 32835U): 1015U/mg, where one unit of PrKX activity is defined as 1nmol phosphate incorporated into PAKtide (RRRLSFAEPG) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 3.944mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

FOR IN VITRO RESEARCH USE ONLY NOT FOR USE IN HUMANS OR ANIMALS

Quality Control Testing

<u>Kinase Assay</u>: 1.3–16.4ng of this lot of enzyme phosphorylated 200µM PAKtide (RRRLSFAEPG) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



<u>MS Tryptic Fingerprint</u>: Confirmed identity as PrKX with the translated native sequence listed on page three.



Eurofins Pharma Discovery Services UK Limited Gemini Crescent Dundee Technology Park DUNDEE DD2 1SW United Kingdom T +44 (0)1382 561600 F +44 (0)1382 561601 www.eurofins.com/pharmadiscovery



Discovery Services

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer: 40mM MOPS-NaOH pH7.0, 1mM EDTA.
- PAKtide (RRRLSFAEPG): Use at a final assay concentration of 200µM. Prepare 2mM stock. Use 2.5µl of stock per assay point.
- **3. PrKX, active:** Dilute with 20mM MOPS-NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 1.3–16.4ng per assay point.
- [γ-³³P]ATP: 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

- 1. Add 5µl of 5 x reaction buffer per assay to wells.
- 2. Add 2.5µl of PAKtide (RRRLSFAEPG).
- 3. Add 2.5µl (1.3–16.4ng) PrKX, active.
- 4. Add 5μ I of dH₂O.
- 5. Add 10µl of diluted [γ -³³P]ATP mixture.
- 6. Incubate for 10 minutes at 30°C.
- 7. Stop the reaction by adding 5µl of 3% phosphoric acid.
- 8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
- 9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
- 10. Wash the filtermat once for 2 minutes with methanol.
- 11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
- 12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.



Discovery Services

Certificate of Analysis

PrKX Sequence Information

Protein human PrKX

Tags N-Terminal 6His

Native sequence M31 of the recombinant sequence is equivalent to M1 of native human PrKX

Accession number GenBank NM_005044

Recombinant PrKX amino acid sequence:

1MSYYHHHHHDYDIPTTENLYFQGAMDPEFMEAPGLAQAAAAESDSRKVAEETPDGAPAL61CPSPEALSPEPPVYSLQDFDTLATVGTGTFGRVHLVKEKTAKHFFALKVMSIPDVIRLKQ121EQHVHNEKSVLKEVSHPFLIRLFWTWHDERFLYMLMEYVPGGELFSYLRNRGRFSSTTGL181FYSAEIICAIEYLHSKEIVYRDLKPENILLDRDGHIKLTDFGFAKKLVDRTWTLCGTPEY241LAPEVIQSKGHGRAVDWWALGILIFEMLSGFPPFFDDNPFGIYQKILAGKIDFPRHLDFH301VKDLIKKLLVVDRTRRLGNMKNGANDVKHHRWFRSVDWEAVPQRKLKPPIVPKIAGDGDT361SNFETYPENDWDTAAPVPQKDLEIFKNF

Recombinant PrKX nucleotide sequence:

1	atgtcgtact	accatcacca	tcaccatcac	gattacgata	tcccaacgac	cgaaaacctg
61	tattttcagg	gcgccatgga	tccggaattc	atggaggcgc	ccgggctggc	ccaggcggcc
121	gcggcggaga	gcgactcccg	caaggtggcg	gaggagaccc	ccgacggggc	gcccgcgctc
181	tgccccagcc	ctgaggcgct	gtcgccggag	ccgcctgtgt	acagcctgca	ggactttgac
241	acgctggcca	ccgtgggcac	tgggacgttc	gggcgggtgc	acctggtgaa	ggagaagaca
301	gccaagcatt	tcttcgccct	caaggtgatg	agcattcctg	acgtcatccg	cctaaagcag
361	gagcaacacg	tacacaatga	gaagtctgtc	ctgaaggaag	tcagccaccc	gttcctcatc
421	aggctgttct	ggacgtggca	tgacgagcgc	ttcctctaca	tgctcatgga	gtacgtgccg
481	ggcggcgagc	tcttcagcta	cctgcgcaac	cggggggcgct	tctccagcac	cacgggggctc
541	ttctactctg	cagagatcat	ctgtgccatc	gagtacctgc	actccaaaga	gatcgtctac
601	agggacttga	agccagagaa	catcctgctg	gatagggatg	gccacattaa	gctcacggac
661	tttgggttcg	ccaagaagct	ggtagacagg	acttggaccc	tctgtggaac	acccgagtac
721	ctagcccccg	aagtcattca	gagcaagggc	cacggaaggg	ccgtggactg	gtgggccctc
781	ggcatcctga	tattcgagat	gctttcgggg	tttcctccgt	tttttgatga	caacccgttt
841	ggcatttatc	agaaaattct	tgcaggcaaa	atagatttcc	ccagacattt	ggatttccat
901	gtaaaagacc	tcattaagaa	actgctcgtg	gttgacagaa	caaggcgatt	aggaaacatg
961	aagaacgggg	cgaatgatgt	gaagcatcat	cggtggttcc	gctccgtgga	ctgggaagct
1021	gttccgcaga	gaaaactgaa	gcctcccatc	gtgcccaaga	tagctggtga	cggcgacact
1081	tccaacttcg	aaacttaccc	tgagaatgac	tgggacacag	ccgcgcccgt	gccgcagaag
1141	gatttagaaa	tcttcaagaa	tttctga			

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.